| Clinical Significance of CD7 Expression in Acute Myelocytic Leukemia |
|
Gye Jin Yoon, Pill Sang Jang, Young Choi, Jun A Lee, Hyo Jung Han, Hyoung Soo Choi, Hee Young Shin, Joong Gon Kim, Hyo Seop Ahn |
|
Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea |
| 급성 골수성 백혈병에서 CD7 양성의 임상적 의미 |
|
윤계진, 장필상, 최영, 이준아, 한효정, 최형수, 신희영, 김중곤, 안효섭 |
|
서울대학교 의과대학 소아과학교실 |
|
|
|
|
| Abstract |
Purpose
: It has been shown that a considerable number of acute myeloid leukemia(AML) patients had both myeloid and lymphoid antigens. CD7 is a lymphoid antigen, often expressed in AML cells. We investigated 40 AML patients to clarify the relationship between the cellular characteristics and clinical features.
Methods
: We reviewed 8 CD7 positive(CD7＋) AML patients and 32 CD7 negative(CD7－) AML patients as a control group. They were diagnosed at Seoul National University Children's Hospital from Jan, 1993 to March, 1997. We analyzed the medical records retrospectively.
Results
: The median age was 3 years in the CD7＋ group and 7 years in the CD7－group. There were no significant differences in sex ratio, WBC counts, hepatomegaly, or CNS invasion of leukemic cells between the two groups. There was frequent expression of HLA-DR in the CD7＋ group(P<0.05). No particular karyotypic abnormality existed in the CD7＋ group. Complete remission was achieved in 42.9% of the CD7＋ group and in 56% of the CD7－ group, while the 2-year survival rate was 44.4±22.2% in the CD7＋ group and 54.9±10.8% in the CD7－ group. There was no significant difference in either remission rate or survival rate between the two groups.
Conclusion
: Although the CD7＋ group showed slightly lower complete remission and survival rates than the CD7－ group, there was no statistically significant difference between the two groups. Further studies are required to determine the prognostic significance of CD7＋ acute myeloid leukemia. |
| Key Words:
Acute myeloid leukemia, Immunophenotype, CD7, Prognostic significance |
|
PDF Links
Download Citation
